B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Pirtobrutinib and CAR T-cell therapy and CAR T-cell therapy have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors.